CAMBRIDGE, Mass., June 24, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc., a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced the closing of its initial public offering of 6,900,000 shares of its common stock at a price to the public of $16.00 per share, before underwriting discounts, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock. All of the common stock was offered by Zafgen. The company's common stock is listed on The NASDAQ Global Market under the symbol "ZFGN."
Leerink Partners LLC and Cowen and Company, LLC acted as joint book-running managers of the offering. Canaccord Genuity Inc. and JMP Securities LLC acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 18, 2014. Copies of the final prospectus relating to the offering may be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 800-808-7525, ext. 4814, or by email at Syndicate@leerink.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by phone 631- 274-2806 / fax 631-254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Media Contact:
Source: Zafgen, Inc.